Live Breaking News & Updates on காடீயேக் அறிவியல்|Page 2
Stay updated with breaking news from காடீயேக் அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nearly two dozen drug companies reported paying their typical employee last year at least $300,000. Most publicly traded companies are required to disclose the compensation of their median employee. Insider pulled these corporate filings from nearly 200 drug companies to analyze pay trends across the industry, including the CEOs who made the most in 2020. Insider s analysis included companies listed in two leading biotech indices the XBI and the IBB as well as a handful of large multinational pharmaceutical companies. We also capped the analysis to companies with a market value of at least $1 billion. Overall, 125 companies reported median employee pay in 2020. Many small or newly public companies aren t required to calculate and disclose that figure. The 23 best-paying companies are listed below. ....
A robust pipeline of potential new treatments currently in Phases II and III is expected to drive the Diabetic Retinopathy Market ahead. LAS VEGAS, May 12, 2021 /PRNewswire/ DelveInsight's ....
Diabetic Macular Edema Market: Revenues Estimated to Climb Modestly at a CAGR of 3.2% During the Study Period 2018-2030 in the 7MM, Foresees DelveInsight LAS VEGAS, May 10, 2021 /PRNewswire/ DelveInsight s Diabetic Macular Edema (DME) Market report offers detailed information on current treatment practices, emerging drugs, Diabetic Macular Edema market share of the individual therapies, current and forecasted Diabetic Macular Edema market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). Key highlights from the The total Diabetic Macular Edema prevalent population in the 7MM was 1,862,529 in 2020. The United States accounted for the maximum DME prevalent cases, while France reported the least. ....
Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Kodiak Sciences (NASDAQ:KOD) were tumbling 11.1% lower as of 12:07 p.m. EDT on Monday. The decline came after the company provided its first-quarter update. So what Kodiak reported a net loss in Q1 of $0.98 per share with no revenue. That bottom-line result was a little worse than the average analysts estimate of a net loss of $0.97 per share. However, the sell-off of the biotech stock probably stemmed more from another announcement. ....
Evercore ISI Reaffirms Their Buy Rating on Amgen (AMGN) analystratings.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from analystratings.com Daily Mail and Mail on Sunday newspapers.